Advice - reimburse lebrikizumab (Ebglyss®) for the treatment of moderate to severe eczema
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse lebrikizumab (Ebglyss®) from the basic health insurance package. This medicinal product can be used in certain patients with eczema. The reason for this advice was the medicinal product being placed in what is known as the ‘lock procedure for expensive medicinal products’.
Lebrikizumab is intended for people who have eczema because of a genetic predisposition
Lebrikizumab is the active substance; the brand name is Ebglyss®. The medicinal product is an injection that is given under the skin.
The medicinal product can be used in people with eczema due to a hereditary predisposition. In eczema, patches of the skin are itchy, can become reddened or may have flakes, bumps, fissures or scabs. The manufacturer has requested reimbursement for the treatment of moderate to severe atopic eczema in adults and adolescents aged 12 and above who are eligible for systemic treatment.
Advice from the National Health Care Institute on the reimbursement of lebrikizumab
The National Health Care Institute advises the Minister of VWS to reimburse lebrikizumab (Ebglyss®) from the basic health insurance package.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The National Health Care Institute advises the minister on issuing a package recommendation. The Minister makes the final decision whether or not to reimburse the medication from the basic health care package.
Lock procedure for expensive medicinal products
The Minister has placed lebrikizumab for this indication in the lock procedure for expensive medicinal products. A medicinal product in this lock procedure will not be eligible for reimbursement from the basic health care package until:
- there is a positive package advice from the National Health Care Institute;
- there are arrangements and safeguards for appropriateness in place;
- price reductions have been successfully negotiated with the manufacturer.
For more information, see the page ‘Lock procedure for expensive medicinal products’.